var data={"title":"Ceftaroline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ceftaroline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/434730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ceftaroline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ceftaroline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ceftaroline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390165\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Teflaro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10953358\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Fifth Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426126\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> IV: 600 mg every 12 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infection:</b> IV: 600 mg every 12 hours for 5 to 14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46725970\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ceftaroline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community acquired: </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants &ge;2 months and Children &lt;2 years:</i> 8 mg/kg/dose every 8 hours for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &ge;2 years and Adolescents &lt;18 years:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;33 kg: 12 mg/kg/dose every 8 hours for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;33 kg: 400 mg every 8 hours <b>or</b> 600 mg every 12 hours for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adolescents &ge;18 years:</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infection: </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants &ge;2 months and Children &lt;2 years:</i> 8 mg/kg/dose every 8 hours for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &ge;2 years and Adolescents &lt;18 years:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;33 kg: 12 mg/kg/dose every 8 hours for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;33 kg: 400 mg every 8 hours <b>or</b> 600 mg every 12 hours for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adolescents &ge;18 years:</i> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426127\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426124\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Adult: Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to &le;50 mL/minute: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;15 to &le;30 mL/minute: 300 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD patients receiving hemodialysis: 200 mg every 12 hours; dose should be given after hemodialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Infants &ge;2 months, Children, and Adolescents &lt;18 years: Note:</b> Renal function may be estimated using the Schwartz equation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute/1.73m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute/1.73m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; data are insufficient; use with caution; dosage adjustment may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682548\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, ceftaroline is primarily renally eliminated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390166\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Teflaro: 400 mg (1 ea); 600 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426096\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426128\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer by slow IV infusion over 5 to 60 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10953360\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> Treatment of community-acquired bacterial pneumonia in adults and pediatric patients 2 months of age and older caused by <i>Streptococcus pneumoniae</i> (including cases with concurrent bacteremia), <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only), <i>Haemophilus influenzae</i>, <i>Klebsiella pneumoniae</i>, <i>Klebsiella oxytoca</i>, and <i>Escherichia coli</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of acute bacterial skin and skin structure infections in adults and pediatric patients 2 months of age and older caused by <i>Staphylococcus aureus</i> (including methicillin-susceptible and methicillin-resistant isolates), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Klebsiella oxytoca</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426102\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">The following reactions occurred in all indicated populations unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Hematologic &amp; oncologic: Positive direct Coombs test (infants, children, and adolescents: 18%; adults: 10% to 11%; no evidence of hemolysis in any treatment group)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (adults: &lt;2%), palpitations (adults: &lt;2%), phlebitis (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (adults: 3% to 4%), headache (infants, children, and adolescents: &lt;3%), dizziness (adults: &lt;2%), seizure (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3% to 7%), pruritus (infants, children, and adolescents: &lt;3%), urticaria (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (adults: 2%), hyperglycemia (adults: &lt;2%), hyperkalemia (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (5% to 8%), vomiting (2% to 5%), nausea (3% to 4%), constipation (adults: 2%), abdominal pain (adults: &lt;2%), pseudomembranous colitis (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (adults: &lt;2%), eosinophilia (adults: &lt;2%), neutropenia (adults: &lt;2%), thrombocytopenia (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (infants, children, and adolescents: &lt;3%), increased serum AST (infants, children, and adolescents: &lt;3%), increased serum transaminases (adults: 2%), hepatitis (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis (adults: &lt;2%), hypersensitivity (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (adults: &lt;2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis (adults), leukopenia (adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426100\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known serious hypersensitivity to ceftaroline, other members of the cephalosporin class, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426101\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia:  Seroconversion from a negative to a positive direct Coombs&rsquo; test has been reported.  Hemolytic anemia was not reported in clinical studies; however, if anemia develops during or after treatment, consider drug-induced hemolytic anemia.  Diagnostic tests should include a direct Coombs&rsquo; test.  If hemolytic anemia is suspected, discontinue the drug and institute supportive care as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious hypersensitivity (anaphylactic) and skin reactions have occurred with ceftaroline. Use with caution in patients with a history of penicillin, cephalosporin, or carbapenem allergy. Maintain clinical supervision if given to penicillin or beta-lactam allergic patients; cross sensitivity among beta-lactam antibacterial agents has been reported. If a serious reaction occurs, discontinue the drug and institute supportive measures as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis (including fatalities); CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &le;50 mL/minute); dosage adjustments recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298995\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11429548\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16088&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426098\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20613466\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ceftaroline fosamil is excreted in breast milk. The manufacturer recommends that caution be exercised when administering ceftaroline fosamil to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426132\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Obtain specimen for culture and susceptibility prior to the first dose. Monitor for signs of anaphylaxis during first dose. Monitor renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426114\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) 1 through 3. This action blocks the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls and inhibits cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested. Ceftaroline has a strong affinity for PBP2a, a modified PBP in MRSA, and PBP2x in <i>S. pneumoniae</i>, contributing to its spectrum of activity against these bacteria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11426116\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>The pharmacokinetics of ceftaroline in pediatric patients from 2 months to &lt;18 years of age were similar to those in adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Median: 20.3 L (range: 18.3 to 21.6 L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Ceftaroline fosamil (inactive prodrug) undergoes rapid conversion to bioactive ceftaroline in plasma by phosphatase enzyme; ceftaroline is hydrolyzed to form inactive ceftaroline M-1 metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~1.6 hours (single dose); ~2.66 hours (multiple dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~88%); feces (~6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322874\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Teflaro Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (1): $210.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (1): $210.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059488\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Zinforo (AR, AT, AU, BE, BR, CH, CR, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, HU, IE, IL, IS, LB, LT, LU, MT, MY, NI, NL, NO, NZ, PA, PL, PT, RO, SE, SG, SI, SK, SV, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Biek D, Critchley IA, Riccobene TA, et al, &quot;Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin With Expanded Anti-Gram-Positive Activity,&quot; <i>J Antimicrob Chemother,</i> 2010, 65(Suppl 4):iv9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftaroline-drug-information/abstract-text/21115457/pubmed\" target=\"_blank\" id=\"21115457\">21115457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corey GR, Wilcox M, Talbot GH, et al, &quot;Integrated Analysis of CANVAS 1 and 2: Phase 3,Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Complicated Skin and Skin-Structure Infection,&quot; <i>Clin Infect Dis</i>, 2010, 51(6):641-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftaroline-drug-information/abstract-text/20695801/pubmed\" target=\"_blank\" id=\"20695801\">20695801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    File TM Jr, Low DE, Eckburg PB, et al, &quot;Integrated Analysis of FOCUS 1and FOCUS 2: Randomized, Double-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone in Patients With Community-Acquired Pneumonia,&quot; <i>Clin Infect Dis</i>, 2010, 51(12):1395-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftaroline-drug-information/abstract-text/21067350/pubmed\" target=\"_blank\" id=\"21067350\">21067350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftaroline-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teflaro (ceftaroline fosamil) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yam FK, Kwan BK, &quot;A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline,&quot; <i>AM J Health-Syst Pharm</i>, 2014, 71(17):1457-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftaroline-drug-information/abstract-text/25147169/pubmed\" target=\"_blank\" id=\"25147169\">25147169</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16088 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F11390165\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10953358\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11426126\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46725970\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F11426127\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11426124\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682548\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F11390166\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F11426096\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11426128\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10953360\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11426102\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11426100\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11426101\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298995\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11429548\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11426098\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20613466\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11426132\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11426114\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11426116\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322874\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059488\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16088|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ceftaroline-patient-drug-information\" class=\"drug drug_patient\">Ceftaroline: Patient drug information</a></li><li><a href=\"topic.htm?path=ceftaroline-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftaroline: Pediatric drug information</a></li></ul></div></div>","javascript":null}